Aimei Vaccine (06660) announced that the Phase III clinical trial of the group's 13-valent pneumococcal polysaccharide conjugate investigational vaccine started recruiting subjects at five sites, including Lincang and Dali in Yunnan in February 2022, with a total of 3780 enrolled subjects. The trial is currently in the phase of blood sample collection six months after full vaccination, with the basic immunogenicity MOPA serum testing completed to date and statistical unblinding set to begin soon.

On October 8th, vice president Chen Bilian, Tao Qiaofeng, director of the Biological Products Institute, Zhou Minghao, key personnel He Kailun, and Shao Jiamei from the Zhejiang Food and Drug Inspection Research Institute visited Aimei Vaccine's subsidiaries Aimei Rong'an and Aimei Weixin for investigation, research, and guidance. Zhu Nan, general manager of Aimei Weixin, and Hu Dedong, deputy general manager of Aimei Rong'an, led the team to welcome the experts from the Zhejiang Provincial Drug Inspection Institute, expressing sincere gratitude on behalf of the group's senior management.

Aimei Vaccine (06660) announced its decision to initiate the plan for the first public offering of RMB ordinary shares and listing (A-share listing) to promote business development, enhance comprehensive competitiveness, and ensure the realization of the company's operational goals and future development strategies. The board of directors has approved the related work for the A-share listing.

Aimei Vaccine (06660) announced that its freeze-dried human rabies vaccine (serum-free Vero cell) has completed the full-course vaccination safety observation seven days after the first dose in the phase III clinical trial on September 18th, indicating good safety from the first dose to seven days after the entire course. As a product iteration upgrade, there is currently no serum-free rabies vaccine approved for marketing in the market.

The Chinese Preventive Medicine Association recently held the Conference on Adult Hepatitis B Screening and Immunization Strategy in Beijing. Aimei Vaccine, as China's largest hepatitis B vaccine manufacturer, attended the meeting as a collaborator and participated in the "Expert Consensus on Immunization Strategy for Adult Hepatitis B Vaccination in China" project.

Aimei Vaccine（06660.HK） has received approval to issue non-publicly listed RMB common shares (i.e., domestic shares) to specific entities, according to its latest announcement on August 30.

According to Aimei Vaccine (06660), the company announced that on August 28, 2023, a randomized, double-blind, controlled trial of a 23-valent pneumococcal polysaccharide vaccine phase III was initiated at the disease control center of a southern county in Sichuan Province. This research will be conducted at two sites in Sichuan Province and one site in Shandong Province, planning to enroll 1,920 healthy subjects aged 2 or above.

Aimei Vaccine's application for clinical trials of the human rabies mRNA vaccine has recently been accepted by the Chinese drug regulatory authority (CDE). This marks the first domestically declared clinical application for a rabies mRNA vaccine.

On May 26th, the "Invest in Beijing Global Summit," hosted by the Beijing Municipal Government, was held at the Zhongguancun National Independent Innovation Demonstration Zone Exhibition Center. As a key investment attraction enterprise in the Beijing Economic and Technological Development Zone, Aimei Vaccine was invited to attend the summit and the signing ceremony for significant projects. As a leading domestic vaccine industry enterprise, Aimei Vaccine participated in the summit along with Fortune Global 500 companies, central enterprises, unicorn enterprises, fund companies, investment institutions, and other market entities.